Related Experiment Video

Updated: Jul 20, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

[Hyperhomocystinemia as a thrombotic risk factor in patients suffering from systemic lupus erithematosus and

Laura Onetti¹, Susana Villafañe, Emilia Menso

¹Servicio de Reumatología, UHMI 1, Hospital Nacional de Clínicas, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba.

Revista De La Facultad De Ciencias Medicas (Cordoba, Argentina)

|September 16, 2006

Insights

Hyperhomocysteinemia is prevalent in Systemic Lupus Erythematosus (SLE) patients, particularly those with antiphospholipid syndrome. Elevated homocysteine (Hcy) levels correlate with antiphospholipid antibodies, indicating a potential risk factor for thrombotic events in SLE.

Area of Science:

Rheumatology
Clinical Chemistry
Immunology

Context:

Systemic Lupus Erythematosus (SLE) is an autoimmune disease associated with an increased risk of thrombosis.
Antiphospholipid syndrome (APS) is a common complication of SLE, further elevating thrombotic risk.
Hyperhomocysteinemia (Hcy), an elevated level of homocysteine, is a potential risk factor for cardiovascular and thrombotic diseases.

Purpose:

To determine the prevalence of hyperhomocysteinemia (Hcy) in SLE patients with and without antiphospholipid syndrome (APS).
To compare Hcy levels between SLE patients (with and without APS) and healthy controls.
To investigate the correlation between hyperhomocysteinemia and antiphospholipid antibodies in SLE patients.

Summary:

This study included 44 SLE patients (17 with APS, 27 without) and 24 healthy controls.
Clinical and laboratory tests were performed, including anticardiolipin antibodies, lupus anticoagulant, and Hcy levels. Hcy > 9 was considered abnormal.
Hyperhomocysteinemia was detected in 61.4% of SLE patients, with higher prevalence in those with APS. Statistically significant differences in Hcy levels were observed between SLE patients (with and without APS) and controls. A correlation was found between hyperhomocysteinemia and anticardiolipin antibodies.

Impact:

Findings suggest hyperhomocysteinemia is a significant risk factor in SLE, especially in the presence of APS.
Elevated Hcy levels in SLE patients may contribute to thrombotic manifestations.
This study highlights the importance of monitoring Hcy levels in SLE patients for risk stratification and potential therapeutic interventions.

Read full analysis

Abstract

Objectives:

to detect the prevalence of hyperhcy in SLE patients with and without antiphospholipid syndrom; to compare the Hcy levels between those patients and healthy controls and to determine the correlation between hyperhcy and antiphospholipid antibodies.

Patients And Methods:

we studied 44 SLE patients: 17 had antiphospholipid syndrom and 27 didn't have it, and we compared them to 24 healthy controls. All of them where checked clinically and with laboratory tests like anticardiolypin antibodies, lupus anticoagulant and Hcy. Hcy > 9 was considered abnormal. Patient who had hyperhcy were treated with folic acid+vitB6+vitB12 a month along.

Statistical Analysis:

cualytative variables: chi square or Fischer's; cuantitative variables: Student's T test or Mann-Whitney's test.

Results And Conclusions:

there were 35 trombotic manifestations in 44 patients. Hyperhcy was present in 27 SLE patients (61,4%), 12 of them had antiphospholipid syndrom. Hcy concentrations patients vs.controls was statisticaly different (p= 0,002). There was also stastisticaly different the hcy concentration from SLE patients with SAF vs controls (p=0,003) and without SAF vs controls (p= 0,015). From 33 SLE patients, 20 (33%) were aCL(+). 15(75%) of them had hiperhcy.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Articles linked to this work by shared authors, journal, and citation graph.

Age-Specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data From the Centers for Disease Control and Prevention Lupus Registries.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Impact of an online lupus self-management programme in an established, population-based cohort of adults with diagnosed SLE: a mixed-methods study.

Lupus science & medicine·2026

Protective effect of antimalarials on the most frequently affected damage domains in SLE: Data from a multiethnic Latin American cohort.

Lupus·2026

Programme evaluation of Strategies to Embrace Living with Lupus Fearlessly (SELF): an evidence-based digital programme to build and improve lupus self-management skills.

Lupus science & medicine·2025

Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort.

Lupus science & medicine·2025

Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA.

Lupus science & medicine·2025

See all related articles